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Introduc?on,	  purpose	  and	  objec?ves.	  
β	  -­‐	  thalassemia	  is	  a	  monogenic	  blood	  disorder	  that	  is	  characterized	  by	  reduced	  or	  
absence	  of	  β	   -­‐	  globin	  produc9on,	   resul9ng	   in	  anemia.	  Current	   therapies	   include	  
blood	   transfusion	   combined	   with	   iron	   chela9on,	   and	   the	   s9mula9on	   of	   fetal	  
hemoglobin.	  BM	  and	  cord	  blood	  transplanta9on,	  although	  are	   the	  only	  cura9ve	  
treatments,	  are	  restricted	  by	  the	  matched	  donor	  limita9on.	  
	  
Different	   gene	   therapy	   strategies	   have	   been	   evolving	   in	   the	   last	   years	  with	   the	  
aim	  to	  develop	  an	  efficient	  and	  effec9ve	  cura9ve	  treatment	  for	  this	  disease.	  The	  
success	   of	   gene	   therapy	   lies	   on	   the	   desing	   of	   efficient	   globin	   vectors,	   like	  
len9viruses,	   that	   can	   effec9vely	   and	   stably	   transduce	   HSCs	   and	   on	   the	  
improvement	   of	   the	   iPSC	   reprogramming	   techniques,	   aiming	   to	   achieve	   higher	  
yield	  of	  gene9cally	  modified	  HSCs.	  	  
	  
Since	  gene	  therapy	  development	  is	  growing	  so	  fast,	  the	  purpose	  of	  this	  research	  
paper	  is	  going	  to	  be	  an	  easy	  explana9on	  of	  β	  –	  thalassemia	  and	  its	  gene	  therapy,	  
that	   will	   facilitate	   the	   pa9ents	   and	   its	   families	   to	   become	   familiar	   with	   the	  
mechanismis	  of	  the	  two	  most	  promising	  treatements.	  
	  
In	  this	  poster	  is	  shown	  the	  informa9on	  used	  to	  do	  the	  booklet	  des9nated	  to	  the	  





β	  -­‐	  thalassemia	  is	  a	  blood	  disorder	  that	  produces	  the	  reduc9on	  or	  the	  abcense	  of	  the	  produc9on	  of	  hemoglobin	  A,	  which	  comprises	  
the	  98%	  of	  adult	  human	  hemoglobin.	  Hemoglobin	  is	  composed	  by	  four	  chains:	  2	  α	  globin	  chains	  and	  2	  β	  	  globin	  chains.	  
This	   reduc9on	   or	   absence	   in	   the	   produc9on	   occurs	   when	   the	   gene	   that	   controls	   the	   produc9on	   of	   β-­‐globin	   (HBB)	   is	   defec9ve.	   The	  
accumula9on	  of	  α	  chains	  that	  cannot	  match	  the	  β	  chains	  and	  form	  hemoglobin	  molecules	  leads	  to	  a	  premature	  death	  of	  red	  blood	  cells.	  







































































Figure	  1:	  The	  paXern	  of	  
inheritance:	  autosomal	  
recessive.	  (	  Rare	  
dominant	  paXern	  of	  
inheritance)	  
β	  -­‐	  thalassemia	  is	  caused	  by	  more	  than	  200	  muta9ons,	  mostly	  associated	  with	  one	  or	  limited	  number	  
of	  nucleo9des.	  The	  vast	  majority	  are	  point	  muta9ons	  within	   the	  gene	  or	   its	   immediate	  flanking	  and	  
can	   alter	   the	   transcrip9on,	   the	   RNA	   processing	   and	   the	   mRNA	   transla9on.	   	   These	   muta9ons	   are	  
classified	  according	  to	  whether	  the	  corresponding	  allele	  results	   in	  no	  (β0)	  or	   low	  (β+)	  β-­‐globin	  chain	  
synthesis.	  	  
β-­‐	  Talassèmia	  	  
Major	  
-­‐	  Both	  gene	  
copies	  defec9ve	  
(	  β0/β+).	  




-­‐	  Lifelong	  	  
treatement.	  
Intermedia	  
-­‐	  Both	  gene	  copies	  
defec9ve	  (	  β+).	  
-­‐	  Reduc9on	  of	  β-
globin	  produc9on.	  
-­‐	  Wide	  range	  of	  
sypthoms.	  







-­‐	  A	  gene	  copy	  
defec9ve(	  β0/β
+).	  




-­‐No	  need	  for	  
treatment	  in	  



















	  Gene	   therapy:	  modify	   the	  gene9c	  material	  using	   the	  
inser9on	  of	  a	  func9onal	  gene	  into	  a	  living	  cell	  to	  achieve	  a	  
therapeu9c	  effect.	  
	  




-­‐ 	  Current	  treatments	  limitated.	  
Len?virus:	  
-­‐ 	  Retrovirus	  
-­‐ 	  Dividing	  non	  dividing	  cells	  




-­‐ 	  Problems:	  RCL	  and	  inser9onal	  toxicity	  	  
-­‐ 	  SIN	  vector	  
-­‐ Third	  genera9on	  packaging	  system	  











Figure	  2:	  HIV	   genome.	   LTR;	  Unstranslated	  promoter	   region.	  Gag;	  matrix,	   capsid,	   nucleocapsid	   and	  P6	  protein.	   Pol;	   protease,	  
integrase	  and	  reverse	  transcriptase.	  Vif;	   infec9vity	  for	  cell-­‐free	  transmission.	  Vpr;	  transac9vator,	  entry	   into	  non-­‐dividing	  cells.	  
Vpu;	   virus	   export	   facilitator.	   Tat;	   transcrip9onal	   ac9vator.	   Rev;	   regulator	   of	   structural	   gene	   expression.	   Env;	   envelope	  
glycoproteins.	  Nef;	  CD4	  downregula9on,	  unknown	  in	  vivo	  phatogene9c	  func9on. 
Fig.3:	   Third	   genera9on	   packaging	   method	   using	   a	  
SIN	  vector.	  The	  packaging	  plasmid	  contains	   the	  gag	  
and	   pol	   genes	   under	   the	   influence	   of	   a	   promoter.	  
The	   rev	   plasmid	   expresses	   rev	   cDNA.	   The	   transfer	  
vector	   plasmid	   contains	   HIV-­‐1	   cis-­‐ac9ng	   sequences	  
and	   an	   expression	   casseXe	   for	   the	   transgene.	   It	   is	  
the	   only	   por9on	   transferred	   to	   the	   target	   cells	   and	  
does	   not	   contain	   wild-­‐type	   copies	   of	   the	   HIV	   LTR.	  
The	   5’	   LTR	   is	   chimeric,	   with	   the	   RSV	   enhancer	   and	  
promoter	   replacing	   the	   U3	   region	   to	   rescue	  
transcrip9onal	  dependence	  on	  tat.	  The	  3’	  LTR	  has	  an	  
almost	  completely	  deleted	  U3	  
region.	  The	  envelope	  plasmid	  encodes	  a	  
heterologous	  envelope	  to	  pseudotype	  the	  vector,	  
here	  shown	  coding	  for	  vesicular	  stoma99s	  virus	  
(VSV)-­‐G. 





Fig.4:	   	   Gene	   therapy	   with	   len?viral	   vectors.	  	  
Genera9on	   of	   the	   viruses	   usin	   the	   third	  
genera9on	   of	   len9virus	   packaging	   system.	  
Incuba9on	   of	   HSC	   with	   the	   len9viral	   vector.	  
Selec9on	  of	   the	   corrected	  HSC.	   Reintroduc9on	  
of	  corrected	  HSC	  into	  the	  pa9ent. 
iPSCS	  
-­‐ Induced	  pluripotent	  stem	  cells	  from	  mainly	  soma9c	  cells	  
-­‐ Genes	   and	   surface	   proteins	   expressed	   almost	   iden9cal	   to	  
the	  ones	  expressed	  in	  embryonic	  stem	  cells	  
-­‐ Induc9on	   by	   genes	   such	   as	   Oct3/4,	   Sox2,Klf4,	   c-­‐Myc	   or	  
Nanog.	  
-­‐ Correc9on	  by	  gene	  targe9ng	  
-­‐ Genera9on	  of	  every	  type	  of	  cell	  in	  human	  body	  
	  	  
	  
Fig.5:	   iPSCS	   gene	   therapy.	  
Extrac9on	  of	   soma9c	   cells	   from	  
the	   pa9ent.	   Reprogramming	  	  
this	   cells	   into	   iPSCs	   using	  
specific	   factors	   and	   genes	  
men9oned	  before.	  
Gene	   targe9ng,	   an	   homologous	  
recombina9on	   technique,	   to	  
insert	   the	   func9onal	   β-­‐globin	  
gene.	  Differen9a9on	  of	  this	  cells	  
into	   HSC.	   Reintroduc9on	   of	   the	  
corrected	  HSC	  into	  the	  pa9ent	  
Soma9c	  cells	  
Soma9c	  cells	  culture	  









A	   lot	   of	   techniques,	   mechanisms	   and	   approaches	   are	  
evolving	   really	   fast.	   Lots	   of	   them	   can	   be	   used	   as	  
treatment	   for	   different	   severe	   disease	   so	   we	   should	  
make	   an	   effort	   upda9ng	   the	   pa9ents	   with	   all	   the	  
informa9on	   that	   they	   may	   need	   in	   a	   way	   that	   can	   be	  















LV	  vectors	  +	  
HSC	  	  
Selec9on	  of	  
corrected	  HSC	  
Inser9on	  of	  
corrected	  HSC	  
